Skip to main content
. Author manuscript; available in PMC: 2018 Mar 30.
Published in final edited form as: Int J Pharm. 2017 Feb 3;520(1-2):275–283. doi: 10.1016/j.ijpharm.2017.01.061

Figure 1.

Figure 1

(A) Fabrication of CaMKIIN-loaded particles (CIP): schematic of the protocol for loading CaMKIIN peptides into PLGA particles (see method for further details). PLGA, poly(lactic-co-glycolic-acid); PLGA-NH2, amine endcapped poly(lactic-co-glycolic-acid); PVA, polyvinyl alcohol; EA, ethyl acetate; Amp, amplitude.

(B) Timeline of in vitro experiments with differentiated H9c2 cells: cells were treated with different formulations of CaMKIIN peptide at t = 0, incubated with ISO at t = 4 and collected at t = 28. CaMKIIN peptide solution (CISol); CaMKIIN loaded particles (CIP); TPP conjugated CaMKIIN loaded particles (TPP-CIP); Isoprenaline (ISO).